Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM8002 plus FOLFOX4 as first-line therapy for unresectable hepatocellular carcinoma
ChiCTR2200060764Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jun 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pumitamig in hepatocellular carcinoma (HCC), sponsored by Zhejiang Cancer Hospital. Primary endpoints: objective response rate and incidence and severity of treatment-related adverse events. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
pumitamig
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200060764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060764.